2017 Press Releases

Keyword Search
 
DateTitle 
03/21/17Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM (valbenazine) for the Treatment of Tardive Dyskinesia
- Phase III study conducted in patients with tardive dyskinesia shows significant and meaningful reduction in symptoms with INGREZZA - INGREZZA clinical development program is largest ever in tardive dyskinesia with over 1,000 persons having participated in 20 clinical trials SAN DIEGO, March 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurologic, psychiatric and endocrine related disorders, announced today that positive result... 
Printer Friendly Version
02/14/17Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017
INGREZZATM New Drug Application PDUFA Action Date of April 11, 2017 Acquired U.S. Rights to Opicapone for Parkinson's Disease Elagolix New Drug Application Submission for Endometriosis Expected in Third Quarter of 2017 Two Phase III Studies of Elagolix in Uterine Fibroids Underway, Top-Line Data End of Year Phase II Study of Valbenazine in Pediatric Tourette Syndrome Expected to Readout in Second Quarter 2017 Phase II Trial for Essential Tremor Drug Candidate NBI-640756 Planned fo... 
Printer Friendly Version
02/09/17Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone
Expands Movement Disorder Franchise with Rights to Commercialize Late Stage Asset for Parkinson's Disease ONGENTYS® (opicapone) Approved in Europe in June 2016 Neurocrine to Host Conference Call and Webcast Today at 4:30pm ET/ 1:30pm PT SAN DIEGO and PORTO, Portugal, Feb. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and BIAL today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North ... 
Printer Friendly Version
02/07/17Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
Conference Call and Webcast Scheduled for Tuesday, February 14, 2017 SAN DIEGO, Feb. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter 2016 results after the Nasdaq market closes on Tuesday, February 14, 2017.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Tuesday afternoon, February 14, 2017 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific... 
Printer Friendly Version
01/17/17Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Tourette Syndrome
Eight Week Study Assessed Safety, Tolerability and Efficacy in 124 Adult Subjects Company to Host Conference Call and Webcast Today at 4:30pm ET/ 1:30pm PT SAN DIEGO, Jan. 17, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the top-line results from the Company's Phase II T-Forward study of INGREZZA™ (valbenazine), a highly-selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in adults with Tourette syndrome. While the study showed ... 
Printer Friendly Version
01/06/17Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer
SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced that David-Alexandre "DA" Gros M.D. has joined the executive management team as President and Chief Operating Officer.   "Neurocrine is very pleased to welcome Dr. Gros as our President and Chief Operating Officer as we move forward with our transformation into a commercial entity," said Kevin Gorman, Chief Executive Of... 
Printer Friendly Version
01/05/17Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia
Company to Host Conference Call and Webcast Today, January 5th at 4:30pm ET / 1:30pm PT SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA), after further review of the INGREZZA™ (valbenazine) New Drug Application (NDA), has decided to cancel the Psychopharmacologic Drugs Advisory Committee meeting which was originally scheduled for February 16, 2017. The FDA informed the Company that the Priority... 
Printer Friendly Version
01/03/17Neurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare Conference
Live Audio Webcast will be on January 9, 2017 SAN DIEGO, Jan. 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. The live presentation takes place on Monday, January 9 at 2:30pm PT (5:30pm ET).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   ... 
Printer Friendly Version